Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12A multiple myeloma sensitive Panobinostat Preclinical Actionable In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMD: 19490892, PMID: 22693356). 19490892 22693356
KRAS G12A colorectal cancer sensitive Cetuximab Preclinical Actionable In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391). 25838391
KRAS G12A lung cancer sensitive RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 inhibited proliferation of lung cancer cell lines harboring KRAS G12A in 3D culture (PMID: 30104724). 30104724
KRAS G12A multiple myeloma sensitive PI3K Inhibitor (Pan) CUDC-907 Preclinical Actionable In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356). 19490892 22693356
KRAS G12A colorectal cancer resistant Regorafenib Preclinical Actionable In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391). 25838391
Clinical Trial Phase Therapies Title Recruitment Status